Given the ongoing SARS-CoV-2 pandemic, identification of immunogenic targets against the
coronavirus spike glycoprotein will provide crucial advances towards the development of …

To fully decipher the immunogenicity of the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) Spike protein, it is essential to assess which part is highly immunogenic in a …

COVID-19 is caused by SARS-CoV-2. 1, 2 By July 25, 2020, globally, 15,672,841 diagnosed
cases and 638,352 deaths were reported (https://coronavirus. jhu. edu/map. html). 3 High …

Antibodies are a principal determinant of immunity for most RNA viruses and have promise
to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 …

The worldwide spread of COVID-19 highlights the need for an efficient approach to rapidly
develop therapeutics and prophylactics against SARS-CoV-2. The SARS-CoV-2 spike …

The protective human antibody response to severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) focuses on the spike (S) protein, which decorates the virion surface and …

Summary The SARS-CoV-2 spike (S) glycoprotein contains an immunodominant receptor-
binding domain (RBD) targeted by most neutralizing antibodies (Abs) in COVID-19 patient …

Currently, monoclonal antibodies (MAbs) targeting the SARS-CoV-2 receptor binding
domain (RBD) of spike (S) protein are classified into seven classes based on their binding …

SARS-CoV-2 is a novel betacoronavirus that caused coronavirus disease 2019 and has
resulted in millions of deaths worldwide. Novel coronavirus infections in humans have …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike is the target for
neutralizing antibodies elicited following both infection and vaccination. While extensive …